Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)

There are few effective therapies for small cell lung cancer (SCLC), a highly aggressive disease representing 15% of total lung cancers. With median survival <2 years, SCLC is one of the most lethal cancers. At present, chemotherapies and radiation therapy are commonly used for SCLC managemen...

Full description

Bibliographic Details
Main Authors: Alexander Y. Deneka, Yanis Boumber, Tim Beck, Erica A. Golemis
Format: Article
Language:English
Published: MDPI AG 2019-09-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/11/9/1297